• Alias: CMC-544
    • A CD22-targeted cytotoxic immunoconjugate composed of a humanized IgG4 anti-CD22 antibody that is linked to a calicheamicin dimethyl hydrazide (CalichDMH), a potent cytotoxic antibiotic
    • Currently in phase 2 and 3 clinical trials in hematologic malignancies
    • Recommended phase 2 dose: 0.4 to 2.4 mg/m2 IV every 3 to 4 weeks
    • Half-life: Range from 17 to 230 hours
    • Common side effects: Thrombocytopenia, asthenia, abdominal pain, transaminitis (increased AST/ALT and alkaline phosphatase), neutropenia, fever
    (Advani et al., 2010)
    Other topics in Targeted and Immunotherapy Agents